Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second panel on cost-effectiveness in health and medicine

JAMA - Journal of the American Medical Association

Volumn 316, Issue 10, 2016, Pages 1093-1103

  Sanders, Gillian D ^a   Neumann, Peter J ^b   Basu, Anirban ^c   Brock, Dan W ^d   Feeny, David ^e   Krahn, Murray ^f,g,h   Kuntz, Karen M ⁱ   Meltzer, David O ^j   Owens, Douglas K ^k,l   Prosser, Lisa A ^m,n   Salomon, Joshua A ^o   Sculpher, Mark J ^p   Trikalinos, Thomas A ^q   Russell, Louise B ^r   Siegel, Joanna E ^s   Ganiats, Theodore G ^t  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MCMASTER UNIVERSITY   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY HEALTH NETWORK   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ UNIVERSITY OF MINNESOTA   (United States)

^j UNIVERSITY OF CHICAGO   (United States)

^k VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^l STANFORD UNIVERSITY   (United States)

^m UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

ⁿ UNIVERSITY OF MICHIGAN   (United States)

^o HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^p UNIVERSITY OF YORK   (United Kingdom)

^q BROWN UNIVERSITY   (United States)

^r RUTGERS UNIVERSITY   (United States)

^s PATIENT CENTERED OUTCOMES RESEARCH INSTITUTE   (United States)

^t UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; GOVERNMENT; HEALTH CARE COST; HEALTH CARE FACILITY; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; QUALITY CONTROL; REVIEW; CONSENSUS; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE DELIVERY; MEDICINE; PRACTICE GUIDELINE; PROCEDURES; STANDARDS; TRENDS;

CONSENSUS; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; GUIDELINES AS TOPIC; HUMANS; MEDICINE; QUALITY OF HEALTH CARE;

EID: 84995877260     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.12195     Document Type: Review

References (41)

1. Gold MR, Siegel JE, Russell LB,Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
2. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC; Panel on Cost-Effectiveness in Health and Medicine. The role of cost-effectiveness analysis in health and medicine. JAMA. 1996;276 (14):1172-1177.
3. Siegel JE,Weinstein MC, Russell LB, Gold MR; Panel on Cost-Effectiveness in Health and Medicine. Recommendations for reporting cost-effectiveness analyses. JAMA. 1996;276(16):1339-1341.
4. Weinstein MC, Siegel JE, Gold MR, KamletMS, Russell LB. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276(15):1253-1258.
5. Advisory Committee on Immunization Practices (ACIP). ACIP: guidance for health economics studies. http://www.cdc.gov/vaccines/acip/committee/guidance/economic-studies.html. Accessed May 22, 2015.
6. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal, 2013: PMG9. https://www.nice.org.uk/process/pmg9/chapter/1-foreword. Accessed August 16, 2016.
7. Centers for Medicare & Medicaid Services. National health expenditures; aggregate and per capita amounts, annual percent change and percent distribution: calendar years 1960-2014. http://www.cms.gov/research-statistics-data-And-systems/statistics-trends-And-reports/nationalhealthexpenddata/nationalhealthaccountshistorical.html. Accessed July 22, 2016.
8. Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, eds. Cost-Effectiveness in Health and Medicine. 2nd ed. New York, NY: Oxford University Press; 2016.
9. Daigle ME,Weinstein AM, Katz JN, Losina E. The cost-effectiveness of total joint arthroplasty: a systematic review of published literature. Best Pract Res Clin Rheumatol. 2012;26(5):649-658.
10. Diaby V, Tawk R, Sanogo V, Xiao H, Montero AJ. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. Breast Cancer Res Treat. 2015;151(1):27-40.
11. Neumann PJ. Costing and perspective in published cost-effectiveness analysis. Med Care. 2009;47(7)(suppl 1):S28-S32.
12. Garrison LP Jr, Mansley EC, Abbott TA III, Bresnahan BW, Hay JW, Smeeding J. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report-part II. Value Health. 2010;13(1):8-13.
13. Brettschneider C, Djadran H, Härter M, Löwe B, Riedel-Heller S, König HH. Cost-utility analyses of cognitive-behavioural therapy of depression: a systematic review. Psychother Psychosom. 2015; 84(1):6-21.
14. Kokorowski PJ, Routh JC, Nelson CP. Quality assessment of economic analyses in pediatric urology. Urology. 2013;81(2):263-267.
15. Stone PW, Chapman RH, Sandberg EA, Liljas B, Neumann PJ. Measuring costs in cost-utility analyses: variations in the literature. Int J Technol Assess Health Care. 2000;16(1):111-124.
16. Brouwer WB, Culyer AJ, van Exel NJ, Rutten FF. Welfarism vs extra-welfarism. J Health Econ. 2008;27(2):325-338.
17. Drummond MF, Sculpher MJ, Claxton K, Torrance GW, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 4th ed. Oxford, England: Oxford University Press; 2015.
18. Grosse SD, Krueger KV, MvunduraM. Economic productivity by age and sex: 2007 estimates for the United States. Med Care. 2009;47(7)(suppl 1):S94-S103.
19. Krol M, BrouwerW, Sendi P. Productivity costs in health-state valuations: does explicit instruction matter? Pharmacoeconomics. 2006;24(4):401-414.
20. Meltzer D, Johannesson M. Inconsistencies in the "societal perspective" on costs of the Panel on Cost-Effectiveness in Health and Medicine. Med Decis Making. 1999;19(4):371-377.
21. Meltzer DO,Weckerle CE, Chang LM. Do people consider financial effects in answering quality of life questions? Med Decis Making. 1999;19(3):517.
22. Sculpher MJ, O'Brien BJ. Income effects of reduced health and health effects of reduced income: implications for health-state valuation. Med Decis Making. 2000;20(2):207-215.
23. Sendi P, Brouwer WB. Is silence golden? a test of the incorporation of the effects of ill-health on income and leisure in health state valuations. Health Econ. 2005;14(6):643-647.
24. Shiroiwa T, Fukuda T, Ikeda S, Shimozuma K. QALY and productivity loss: empirical evidence for "double counting." Value Health. 2013;16(4):581-587.
25. Tilling C, Krol M, Tsuchiya A, Brazier J, BrouwerW. In or out? income losses in health state valuations: a review. Value Health. 2010;13(2): 298-305.
26. Bleichrodt H, Quiggin J. Life-cycle preferences over consumption and health: when is cost-effectiveness analysis equivalent to cost-benefit analysis? J Health Econ. 1999;18(6): 681-708.
27. Feenstra TL, van Baal PH, Gandjour A, Brouwer WB. Future costs in economic evaluation: a comment on Lee. J Health Econ. 2008;27(6): 1645-1649.
28. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ. 1997;16(1):1-31.
29. Lee RH. Future costs in cost effectiveness analysis. J Health Econ. 2008;27(4):809-818.
30. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ. 1997;16(1):33-64.
31. Meltzer D. Future costs in medical cost-effectiveness analysis. In: Jones AM, ed. The Elgar Companion to Health Economics. Cheltenham, England: Edward Elgar Publishing Ltd; 2006:447-454.
32. Meltzer D. Response to "future costs and the future of cost-effectiveness analysis". J Health Econ. 2008;27(4):822-825.
33. Nyman JA. Should the consumption of survivors be included as a cost in cost-utility analysis? Health Econ. 2004;13(5):417-427.
34. Weinstein MC, ManningWG Jr. Theoretical issues in cost-effectiveness analysis. J Health Econ. 1997;16(1):121-128.
35. Husereau D, Drummond M, Petrou S, et al; CHEERS Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Cost Eff Resour Alloc. 2013;11(1):6.
36. Russell LB. The Science of Making Better Decisions About Health: Cost-Effectiveness and Cost-Benefit Analysis, September 2015. Rockville, MD: Agency for Healthcare Research and Quality; 2015.
37. Neumann PJ, Cohen JT,Weinstein MC. Updating cost-effectiveness-the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796-797.
38. Husereau D, Drummond M, Petrou S, et al; ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16(2):231-250.
39. Patient Protection and Affordable Care Act, 42 USC 18001 et seq (2010).
40. PausJenssen AM, Singer PA, Detsky AS. Ontario's formulary committee: how recommendations are made. Pharmacoeconomics. 2003;21(4):285-294.
41. Neumann PJ. Using Cost-Effectiveness Analysis to Improve Health Care: Opportunities and Barriers. New York, NY: Oxford University Press; 2005.